Viridian Therapeutics, Inc. Overview
Pro stress-test →Viridian Therapeutics is a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for patients with serious and rare diseases, with expertise in antibody discovery and protein engineering. The company is positioned for transformational value creation in 2026 with multiple clinical catalysts including FDA regulatory decisions and Phase 3 data readouts.
Strategic Profile
Pro stress-test →Viridian is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED), with a novel portfolio of neonatal Fc receptor (FcRn) inhibitors including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases. With approximately $888 million in cash and investments as of October 2025, the company expects to fund its current business plans through profitability, supported by anticipated milestone payments and future commercial revenues.
Competitive Landscape
Pro stress-test →Viridian competes in the thyroid eye disease and FcRn inhibitor spaces. In TED, competitors include other anti-IGF-1R antibodies and complement inhibitors. In the broader FcRn inhibitor class for autoimmune diseases, competitors include Argenx (efgartigimod) and others in clinical development. Viridian's differentiation lies in its extended half-life candidates and oral/subcutaneous dosing options.
Industry Context
Viridian Therapeutics, Inc. operates in Biopharmaceutical - Rare Diseases & Immunology.
Key facts
Headquarters: Waltham, US